Publication | Open Access

Panitumumab versus cetuximab in patients with chemotherapy-refractory wild-type KRAS exon 2 metastatic colorectal cancer (ASPECCT): a randomised, multicentre, open-label, non-inferiority phase 3 study

OncologyChemotherapy-refractory Wild-type KrasColorectal CancerPathologyMetastatic Colorectal CancerImmune Checkpoint InhibitorMolecular OncologyCancer TreatmentMedicineRadiation OncologyCancer ResearchPanitumumab Versus Cetuximab